SCHEMBL1969108

SCHEMBL1969108

CCn1c(N)c(C#N)c2c(c1=S)CN(C)CC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.45
GAA P10253 6/20 0.45
HPGD P15428 6/20 0.45
LMNA P02545 3/20 0.45
HTT P42858 3/20 0.45
TP53 P04637 1/20 0.45
KDM4E B2RXH2 12/20 0.41
KMT2A Q03164 10/20 0.41
MAPT P10636 10/20 0.41
MEN1 O00255 9/20 0.41
GLA P06280 1/20 0.41
HSD17B10 Q99714 5/20 0.39
CASP1 P29466 4/20 0.39
CASP7 P55210 3/20 0.39
ALOX15 P16050 2/20 0.39
MAPK1 P28482 1/20 0.39
PTK2B Q14289 1/20 0.39
ESR2 Q92731 1/20 0.39
POLB P06746 4/20 0.38
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1964761 0.83 ALDH1A1 (0.58) ALDH1A1GAAHPGDLMNAHTT
SCHEMBL1971220 0.82 ALDH1A1 (0.48) ALDH1A1GAAHPGDLMNAHTT
SCHEMBL13448729 0.81 CYP2C19 (0.34) ALDH1A1GAAHPGDLMNAKDM4E
SCHEMBL1971627 0.71 ALDH1A1 (0.49) ALDH1A1GAAHPGDLMNAHTT
SCHEMBL13415767 0.69 ALDH1A1 (0.47) ALDH1A1GAAHPGDLMNAHTT
SCHEMBL6255233 0.66 ALDH1A1 (0.56) ALDH1A1GAAHPGDLMNAHTT
SCHEMBL13448715 0.65 CYP2C19 (0.38) ALDH1A1GAAHPGDLMNAHTT
SCHEMBL1970629 0.63 MAPT (0.47) ALDH1A1GAAHPGDLMNATP53
SCHEMBL6250858 0.63 ALDH1A1 (0.52) ALDH1A1GAAHPGDLMNAHTT
SCHEMBL7718443 0.62 MAPT (0.67) ALDH1A1GAAHPGDLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334676-B1 SUBSTITUTED 3-AMINO-1-OXO OR THIOXO-1,2,5,6,7,8-HEXAHYDRO-2,7-NAPHTHYRIDINE-4-CARBONITRILES AS SELECTIVE ALPHA 2B ANTAGONISTS ALLERGAN INC (US) 2016-07-06 EP claimed
EP-2334676-A1 SUBSTITUTED 3 -AMIN0- 1-0X0 OR THIOXO-I, 2,5,6,7, 8-HEXAHYDR0-2, 7-NAPHTHYRIDINE-4-CARB0NITRILES AS SELECTIVE ALPHA 2B ANTAGONISTS Allergan, Inc. (US) 2011-06-22 EP claimed
US-20100076194-A1 SUBSTITUTED 3-AMINO-1-OXO OR THIOXO-1,2,5,6,7,8-HEXAHYDRO-2,7-NAPHTHYRIDINE-4-CARBONITRILES ARE SELECTIVE ALPHA 2B ANTAGONISTS ALLERGAN, INC. (US) 2010-03-25 US claimed
WO-2010033393-A1 SUBSTITUTED 3 -AMIN0- 1-0X0 OR THIOXO-I, 2,5,6,7, 8-HEXAHYDR0-2, 7-NAPHTHYRIDINE-4-CARB0NITRILES AS SELECTIVE ALPHA 2B ANTAGONISTS ALLERGAN, INC. (US) 2010-03-25 WO claimed
EP-2334676-B1 SUBSTITUTED 3-AMINO-1-OXO OR THIOXO-1,2,5,6,7,8-HEXAHYDRO-2,7-NAPHTHYRIDINE-4-CARBONITRILES AS SELECTIVE ALPHA 2B ANTAGONISTS ALLERGAN INC (US) 2016-07-06 EP disclosed
EP-2334676-B1 SUBSTITUTED 3-AMINO-1-OXO OR THIOXO-1,2,5,6,7,8-HEXAHYDRO-2,7-NAPHTHYRIDINE-4-CARBONITRILES AS SELECTIVE ALPHA 2B ANTAGONISTS ALLERGAN INC (US) 2016-07-06 EP disclosed
EP-2334676-A1 SUBSTITUTED 3 -AMIN0- 1-0X0 OR THIOXO-I, 2,5,6,7, 8-HEXAHYDR0-2, 7-NAPHTHYRIDINE-4-CARB0NITRILES AS SELECTIVE ALPHA 2B ANTAGONISTS Allergan, Inc. (US) 2011-06-22 EP disclosed
US-20100076194-A1 SUBSTITUTED 3-AMINO-1-OXO OR THIOXO-1,2,5,6,7,8-HEXAHYDRO-2,7-NAPHTHYRIDINE-4-CARBONITRILES ARE SELECTIVE ALPHA 2B ANTAGONISTS ALLERGAN, INC. (US) 2010-03-25 US disclosed
US-20100076194-A1 SUBSTITUTED 3-AMINO-1-OXO OR THIOXO-1,2,5,6,7,8-HEXAHYDRO-2,7-NAPHTHYRIDINE-4-CARBONITRILES ARE SELECTIVE ALPHA 2B ANTAGONISTS ALLERGAN, INC. (US) 2010-03-25 US disclosed
US-20100076194-A1 SUBSTITUTED 3-AMINO-1-OXO OR THIOXO-1,2,5,6,7,8-HEXAHYDRO-2,7-NAPHTHYRIDINE-4-CARBONITRILES ARE SELECTIVE ALPHA 2B ANTAGONISTS ALLERGAN, INC. (US) 2010-03-25 US disclosed
WO-2010033393-A1 SUBSTITUTED 3 -AMIN0- 1-0X0 OR THIOXO-I, 2,5,6,7, 8-HEXAHYDR0-2, 7-NAPHTHYRIDINE-4-CARB0NITRILES AS SELECTIVE ALPHA 2B ANTAGONISTS ALLERGAN, INC. (US) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076194-A1 SUBSTITUTED 3-AMINO-1-OXO OR THIOXO-1,2,5,6,7,8-HEXAHYDRO-2,7-NAPHTHYRIDINE-4-CARBONITRILES ARE SELECTIVE ALPHA 2B ANTAGONISTS ADRA1D, ADRB1, ADRA1B ALDH1A1 357/4885GAA 1925/4885HPGD 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.